--- title: "Gossamer Bio (GOSS) news: reverse split and class action" url: "https://aibio.space/companies/gossamer-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "GOSS reverse split, class action, offering, convertible notes, Nasdaq notice and settlement news: Gossamer Bio regains Nasdaq minimum bid price compliance." --- GOSS Gossamer Bio, Inc. NASDAQ · United States # Gossamer Bio (GOSS) news GOSS reverse split, class action and offering news Listings · 2026-09-28 ## [Gossamer Bio regains Nasdaq minimum bid price compliance](https://aibio.space/news/gossamer-bio-regains-nasdaq-minimum-bid-price-compliance/) Nasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million. ## Latest Gossamer Bio news 1. 2026-08-21 Financings [Gossamer Bio private placement has $150 million committed, $25.0 million at first closing](https://aibio.space/news/gossamer-bio-private-placement-has-150-million-committed-25-0-million/) Gossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval. 2. 2026-08-13 Legal [Gossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10](https://aibio.space/news/gossamer-bio-faces-securities-class-action-lead-plaintiff-named/) Kinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate. 3. 2026-06-17 Debt Financing [Gossamer Bio completes exchange of 2027 convertible notes into secured notes](https://aibio.space/news/gossamer-bio-completes-exchange-2027-convertible-notes-secured-notes/) Gossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt. 4. 2026-06-03 Debt Financing [Gossamer Bio exchanges $181,052,000 of 2027 convertible notes](https://aibio.space/news/gossamer-bio-exchanges-181-052-000-2027-convertible-notes/) Gossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture. 5. 2026-05-18 Debt Financing [Gossamer Bio launches exchange offer for 5.00% convertible notes](https://aibio.space/news/gossamer-bio-launches-exchange-offer-5-00-percent-convertible-notes/) The offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants. 6. 2026-04-09 Listings [Gossamer Bio receives Nasdaq minimum bid price deficiency notice, has until October 5, 2026](https://aibio.space/news/gossamer-bio-receives-nasdaq-minimum-bid-price-deficiency-notice-has/) Gossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days. ## Gossamer Bio at a glance - **Ticker**: GOSS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $57.0 million ### Related companies - [Eli Lilly](https://aibio.space/companies/eli-lilly/) NYSE: LLY - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) NASDAQ: ATOS - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) NASDAQ: VTVT - [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) NASDAQ: APRE - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC - [Cingulate](https://aibio.space/companies/cingulate/) NASDAQ: CING - [Trafalgar International](https://aibio.space/companies/trafalgar-international/) OTC: TRFA - [Bioxytran](https://aibio.space/companies/bioxytran/) OTC: BIXT ### Also on NASDAQ - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) FDMT - [Universe Pharmaceuticals](https://aibio.space/companies/universe-pharmaceuticals/) UPC - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [ADMA Biologics](https://aibio.space/companies/adma-biologics/) ADMA - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK - [Onconetix](https://aibio.space/companies/onconetix/) ONCO ## What Gossamer Bio does Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). Seralutinib is an investigational inhaled small molecule inhibitor of PDGFR, CSF1R and c-KIT, designed to address mechanisms that underlie PAH, including pathological remodeling. The Phase 3 PROSERA trial, a 48-week study in 390 PAH patients, reported topline results in February 2026. Seralutinib showed a placebo-adjusted improvement of 13.3 meters in six-minute walk distance at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025. In the prespecified intermediate- and high-risk subgroup of 234 patients, the placebo-adjusted improvement was 20.0 meters. The company is completing analyses of the PROSERA dataset, engaging the FDA on a regulatory path, and has paused enrollment in the SERANATA trial. It is also evaluating alternatives related to its outstanding convertible notes, and it holds an option agreement with Respira Therapeutics for RT234 in PAH and PH-ILD. | Product or program | What it is | Stage | |---|---|---| | seralutinib | Inhaled PDGFR, CSF1R and c-KIT inhibitor for pulmonary arterial hypertension | Phase 3 | | RT234 | Candidate under an option agreement with Respira Therapeutics for PAH and PH-ILD | | Summarised from the company's [10-K filed Mar 17, 2026](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/goss-20251231.htm). ## Gossamer Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$48.5 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | [$114.7 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | | Research and development | [$174.1 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | [$138.5 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | | Net income (loss) | [-$170.4 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | [-$56.5 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | | Cash from operations | [-$171.3 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | [-$3.5 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | | Cash and equivalents | [$37.7 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000072/) | [$46.1 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | | Short-term investments | [$99.2 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000072/) | [$248.4 million](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $41.1 million, plus short-term investments of $15.9 million, $57.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Gossamer Bio Did Gossamer Bio do a reverse stock split? Our latest story on this, dated Sep 28, 2026: "Gossamer Bio regains Nasdaq minimum bid price compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-regains-nasdaq-minimum-bid-price-compliance/). Is there a class action against Gossamer Bio? Our latest story on this, dated Aug 13, 2026: "Gossamer Bio faces securities class action; lead plaintiff named, amended complaint due Aug. 10". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-faces-securities-class-action-lead-plaintiff-named/). Has Gossamer Bio raised money recently? Our latest story on this, dated Aug 21, 2026: "Gossamer Bio private placement has $150 million committed, $25.0 million at first closing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-private-placement-has-150-million-committed-25-0-million/). Has Gossamer Bio sold convertible notes? Our latest story on this, dated Jun 17, 2026: "Gossamer Bio completes exchange of 2027 convertible notes into secured notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-completes-exchange-2027-convertible-notes-secured-notes/). Has Gossamer Bio received a Nasdaq deficiency notice? Our latest story on this, dated Apr 9, 2026: "Gossamer Bio receives Nasdaq minimum bid price deficiency notice, has until October 5, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-receives-nasdaq-minimum-bid-price-deficiency-notice-has/). Has Gossamer Bio settled a lawsuit? Our latest story on this, dated Jun 3, 2026: "Gossamer Bio exchanges $181,052,000 of 2027 convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/gossamer-bio-exchanges-181-052-000-2027-convertible-notes/). What is the ticker symbol of Gossamer Bio? Gossamer Bio, Inc. trades under the ticker GOSS on NASDAQ. Where is Gossamer Bio listed? Gossamer Bio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4GB0. What is the SEC CIK of Gossamer Bio? The SEC Central Index Key (CIK) for Gossamer Bio, Inc. is 1728117. Its filings are on SEC EDGAR. How many shares does Gossamer Bio have outstanding? 488,846,722 shares as of 2026-08-08, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Gossamer Bio listed under? Our directory records Gossamer Bio, Inc. under United States. What does Gossamer Bio do? Our directory classifies Gossamer Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Gossamer Bio? The ISIN recorded for Gossamer Bio, Inc. is US38341P2011. Does aibio.space cover Gossamer Bio? aibio.space lists Gossamer Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Gossamer Bio incorporated? SEC records list its state or country of incorporation as DE. ## Investor discussion: Gossamer Bio Members talk about Gossamer Bio (GOSS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Gossamer Bio, newest first. Each line links the filing it comes from. 1. 2026-09-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000106/goss-20260925.htm) 2. 2026-09-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000094/ex991revstockspliteffectiv.htm) 3. 2026-09-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000091/ex991revstocksplit.htm) 4. 2026-08-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/ex991.htm) 5. 2026-07-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/goss-20260727xexx991xprchi.htm) 6. 2026-07-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000061/goss-20260714.htm) 7. 2026-06-17 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000054/goss-20260617xexx991xprfin.htm) 8. 2026-06-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000052/goss-20260609.htm) 9. 2026-06-02 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000040/goss-20260602xexx991xpr.htm) 10. 2026-05-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,5.02,7.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518xexx991xearni.htm) 11. 2026-05-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000038/goss-20260518.htm) 12. 2026-05-15 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000032/goss-20260331.htm) 13. 2026-04-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000022/goss-20260408.htm) 14. 2026-03-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/goss-20251231.htm) 15. 2026-03-17 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/goss-20251231.htm) 16. 2025-09-25 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000076/goss-20250924.htm) 17. 2025-03-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm) 18. 2025-02-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000004/goss-20250219.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GOSS on TradingView](https://www.tradingview.com/symbols/NASDAQ-GOSS/). ## SEC filings and registration - **SEC name**: Gossamer Bio, Inc. - **CIK**: 1728117 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GOSS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121 - **Phone**: (858) 684-1300 - **Shares outstanding**: 488,846,722 as of 2026-08-08 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000106/goss-20260925.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm) filed 2026-09-23 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000102/goss-20260916.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/goss-20260916.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000094/goss-20260910.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000091/goss-20260909.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000085/goss-20260903.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000079/goss-20260824.htm) filed 2026-08-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001728117), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Gossamer Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GOSS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Gossamer Bio, Inc. - **Ticker**: GOSS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US38341P2011 - **Other listed symbols**: GETTEX:4GB0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GOSS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/gossamer-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Gossamer Bio (GOSS) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/gossamer-bio/